Trial · NCT00280059
Results by group230
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 230
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Seizure-free Participants (Responders) During Efficacy Assessment Phase | Pregabalin | 51.6 | percentage of participants | ||
| Percentage of Seizure-free Participants (Responders) During Efficacy Assessment Phase | Lamotrigine | 67.9 | percentage of participants | ||
| Time to 6 Consecutive Months of Seizure-freedom After 4-week Dose Escalation Phase: All Seizures | Pregabalin | 254 | 95% Confidence Interval 199 to 295 | days | |
| Time to 6 Consecutive Months of Seizure-freedom After 4-week Dose Escalation Phase: All Seizures | Lamotrigine | 183 | 95% Confidence Interval 183 to 209 | days | |
| Exit Due to Adverse Events During the Double-blind Treatment Phase (Including Dose Escalation Phase) | Pregabalin | 33 | participants | ||
| Exit Due to Adverse Events During the Double-blind Treatment Phase (Including Dose Escalation Phase) | Lamotrigine | 31 | participants | ||
| Exit for Any Reason During the Double-blind Treatment Phase (Including Dose Escalation Phase) | Pregabalin | 94 | participants | ||
| Exit for Any Reason During the Double-blind Treatment Phase (Including Dose Escalation Phase) | Lamotrigine | 80 | participants | ||
| Exit Due to Lack of Efficacy After 4-week Dose Escalation Phase | Pregabalin | 78 | participants | ||
| Exit Due to Lack of Efficacy After 4-week Dose Escalation Phase | Lamotrigine | 58 | participants | ||
| Exit Due to Any Reason After 4-week Dose Escalation Phase | Pregabalin | 78 | participants | ||
| Exit Due to Any Reason After 4-week Dose Escalation Phase | Lamotrigine | 58 | participants | ||
| Time to First Seizure After the 4-Week Dose Escalation Phase | Pregabalin | 85 | 95% Confidence Interval 59 to 120 | days | |
| Time to First Seizure After the 4-Week Dose Escalation Phase | Lamotrigine | 211 | 95% Confidence Interval 145 to 342 | days | |
| Median Monthy Seizure Frequency: All Partial Seizures | Pregabalin | Dose-escalation phase (Weeks 1 - 4) (n=329, 330) | 0.0 | Standard Deviation 9.348 | seizures/28 days |
| Median Monthy Seizure Frequency: All Partial Seizures | Lamotrigine | Dose-escalation phase (Weeks 1 - 4) (n=329, 330) | 0.0 | Standard Deviation 27.118 | seizures/28 days |
| Median Monthy Seizure Frequency: All Partial Seizures | Pregabalin | Month 1 (n=314, 308) | 0.0 | Standard Deviation 6.139 | seizures/28 days |
| Median Monthy Seizure Frequency: All Partial Seizures | Lamotrigine | Month 1 (n=314, 308) | 0.0 | Standard Deviation 31.453 | seizures/28 days |
| Median Monthy Seizure Frequency: All Partial Seizures | Pregabalin | Month 2 (n=300, 295) | 0.0 | Standard Deviation 3.382 | seizures/28 days |
| Median Monthy Seizure Frequency: All Partial Seizures | Lamotrigine | Month 2 (n=300, 295) | 0.0 | Standard Deviation 28.839 | seizures/28 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00280059/results